The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the effect of increased dosing of clopidogrel and adding cilostazol to standard dose of clopidogrel after the insertion of drug-eluting stent in patients with clopidogrel resistance

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Aspirin; Cilostazol; Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Patient with clopidogrel resistance with treatment of dual antiplatelet agent, aspirin and clopidogrel, for more than 4 weeks after drug-eluting stent

• Clopidogrel resistance is defined as a patients with platelet inhibition less than 30% in platelet function test(VerifyNow-P2Y12 assayTM, Accumetrics, San Diego, CA, USA)

Exclusion Criteria:

• Acute myocardial infarction within 2 weeks

• Unstable angina within 2 weeks

• History of using glycoprotein IIb/IIIa inhibitor within 1 month

• Cerebral infarction within 3 months

• Bleeding diathesis like coagulation disorder, thrombocytopenia (platelet count < 100,000/uL)

• history of gastrointestinal bleeding or genitourinary bleeding within 3 months

• needed oral anticoagulation

• aspirin, clopidogrel or cilostazol hypersensitivity

• congestive heart failure

• serum creatinine level >2mg/dl

• malignancy

• using cytochrome P450 inhibitor (eg, itraconazole)